



JIM GIBBONS
Governor

STATE OF NEVADA
DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
NEVADA MEDICAID

MICHAEL J. WILLDEN
Director

CHARLES DUARTE
Administrator

DRUG USE REVIEW (DUR) BOARD

The Division of Health Care Financing and Policy (DHCFP) Drug Use Review (DUR) Board will conduct a public meeting on **April 28, 2011** beginning at **1:00 p.m.** at the following location:

**Las Vegas Chamber of Commerce
6671 Las Vegas Blvd. S., Suite 300
Las Vegas, NV 89119**

Some members will be attending the conference via video conference at: Nevada State Health Division, 4150 Technology Way, Suite 300, Carson City, Nevada 89706 (seating is limited).

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Rita Mackie at: 775-684-3681 or email rmackie@dhcfp.nv.gov in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Below is an agenda of all items scheduled to be discussed; unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.

Public comment is limited to 5 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.

- i. Call to Order and Roll Call
- ii. *Discussion and Approval of January 27, 2011 Minutes
- iii. Status Update by DHCFP
 - a. Program Updates
- iv. Review of Prescribing/Program Trends
 - a. Top 10 Therapeutic Classes (by Payment and by Claims)
 - b. Top 50 Drugs (by Payment and by Claims)
 - c. Program Trends
- v. Concurrent Drug Utilization Review (ProDUR)
 - a. Review of Q1 2011
 - b. Review of Top Encounters by Problem Type
- vi. Retrospective Drug Utilization Review (RetroDUR)
 - a. Review of Responses
 - b. Status of Previous Quarter
 - c. Status of Current Quarter
 - d. Public Comment
 - e. *Discussion and Action by Board for Future Criterion Selection
- vii. Presentation of Requested Report on Market Share Shift within Thiazolidinediones (TZD) Class
 - a. Public Comment
 - b. *Discussion and Action by Board on Market Share Shift within Thiazolidinediones (TZD) Class

1100 E. William Street, Suite 102, Carson City, Nevada 89701
(775) 684-3600

- viii. Presentation of Updated Medicaid Services Manual Chapter 1200: Prescription Drugs
 - a. Public Comment
 - b. *Discussion and Action by Board on the Review of Updated Medicaid Services Manual Chapter 1200: Prescription Drugs
- ix. Proposed Removal of Prior Authorization Criteria for ramapril (Altace)
 - a. Public Comment
 - b. *Discussion and Action by Board on the Review of proposed removal of clinical prior authorization criteria for ramapril (Altace).
- x. Update on Prior Authorization Criteria for Cox II Inhibitors (Celebrex)
 - a. Public Comment
 - b. *Discussion and Action by Board on the Update Prior Authorization Criteria for Cox II Inhibitors (Celebrex)
- xi. Proposed Prior Authorization Criteria for hydroxyprogesterone caproate (Makena™)
 - a. Public Comment
 - b. *Discussion and Action by Board on the Prior Authorization Criteria for hydroxyprogesterone caproate (Makena™)
- xii. Presentation of Recipient Outreach Programs: Review of Draft Web Announcement on Acetaminophen Dosage Limits
 - a. Public Comment
 - b. *Discussion and Action by Board on Draft Web Announcement on Acetaminophen Dosage Limits
- xiii. Presentation of Recipient Outreach Programs: Smoking Cessation Programs
 - a. Public Comment
 - b. *Discussion and Possible Action by Board on Recipient Outreach Programs: Smoking Cessation
- xiv. Presentation of Requested Report on Utilization and Cost of Proton Pump Inhibitors (PPIs) and H2 Receptor Blockers
 - a. Public Comment
 - b. *Discussion and Action by Board on the Review of Report on Utilization and Cost of Proton Pump Inhibitors (PPIs) and H2 Receptor Blockers
- xv. Presentation of List of Outstanding DUR Board Report Requests
- xvi. Public Comment
- xvii. Date and Location of Next Meeting
- xviii. Adjourn

*** Denotes items, including subparts, on which an action may be taken.**

¹The clinical criteria to be addressed can be found at <http://nevada.fhsc.com>

>>Pharmacy >> Meetings

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (dhcfp.state.nv.us).

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.